Intelligence Feed event · Credit · 2026-10-07

    Vaxcyte prices $1 billion concurrent common stock and convertible note offerings

    Question

    Vaxcyte prices $1 billion concurrent common stock and convertible note offerings

    Direct answer

    Vaxcyte announced the pricing of dual capital raises designed to generate $1 billion in gross funding. The company issued 7.4 million common shares at $64.00 per share alongside pre-funded warrants. The financing package is paired with $500 million in 1.50% convertible senior notes maturing in 2032, securing clinical development capital through long-dated debt.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte prices $1 billion concurrent common stock and convertible note offerings”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1-billion-concurrent-common-stock-and-convertible-note-offerings-8d94be

    CREDIT
    Vaxcyte prices $1 billion concurrent common stock and convertible note offerings
    Vaxcyte announced the pricing of dual capital raises designed to generate $1 billion in gross funding. The company issued 7.4 million common shares at $64.00 per share alongside pre-funded warrants. The financing package is paired with $500 million in 1.50% convertible senior notes maturing in 2032, securing clinical development capital through long-dated debt.
    PCVX
    Impact
    72
    OCT 7
    SIG
    95%
    PCVX
    Vaxcyte prices $1 billion concurrent common stock and convertible note offerings
    Vaxcyte announced the pricing of dual capital raises designed to generate $1 billion in gross funding. The company issued 7.4 million common shares at $64.00 per share alongside pre-funded warrants. The financing package is paired with $500 million in 1.50% convertible senior notes maturing in 2032, securing clinical development capital through long-dated debt.
    → New equity supply and 1.50% convertible debt issuance expand share dilution while extending biotech development liquidity runway.
    Impact
    Vaxcyte announced the pricing of dual capital raises designed to generate $1 billion in gross funding. The company issued 7.4 million common shares at $64.00 per share alongside pre-funded warrants. The financing package is paired with $500 million in 1.50% convertible senior notes maturing in 2032, securing clinical development capital through long-dated debt.
    Affected
    PCVX
    Transmission
    New equity supply and 1.50% convertible debt issuance expand share dilution while extending biotech development liquidity runway.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity dilution and convertible arbitrage hedging pressureMixed1-5dVaxcyte announced pricing of concurrent common stock and $500M convertible note offerings.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month